用于预防或治疗感音神经性听力损失的实验性药物。
Experimental drugs for the prevention or treatment of sensorineural hearing loss.
机构信息
Department of Otolaryngology, Massachusetts Eye and Ear, Boston, MA, USA.
Department of Otolaryngology, Head & Neck Surgery, Harvard Medical School, Boston, MA, USA.
出版信息
Expert Opin Investig Drugs. 2023 Jul-Dec;32(7):643-654. doi: 10.1080/13543784.2023.2242253.
INTRODUCTION
Sensorineural hearing loss results in irreversible loss of inner ear hair cells and spiral ganglion neurons. Reduced sound detection and speech discrimination can span all ages, and sensorineural hearing rehabilitation is limited to amplification with hearing aids or cochlear implants. Recent insights into experimental drug treatments for inner ear regeneration and otoprotection have paved the way for clinical trials in order to restore a more physiological hearing experience. Paired with the development of innovative minimally invasive approaches for drug delivery to the inner ear, new, emerging treatments for hearing protection and restoration are within reach.
AREAS COVERED
This expert opinion provides an overview of the latest experimental drug therapies to protect from and to restore sensorineural hearing loss.
EXPERT OPINION
The degree and type of cellular damage to the cochlea, the responsiveness of remaining, endogenous cells to regenerative treatments, and the duration of drug availability within cochlear fluids will determine the success of hearing protection or restoration.
简介
感音神经性听力损失导致内耳毛细胞和螺旋神经节神经元的不可逆损失。听力检测和言语辨别能力的下降可发生于各个年龄段，而感音神经性听力康复仅限于使用助听器或人工耳蜗进行放大。最近，有关内耳再生和耳保护的实验性药物治疗的新见解为临床试验铺平了道路，以期恢复更生理性的听力体验。与创新的内耳药物输送微创方法的发展相结合，听力保护和恢复的新的、新兴治疗方法已触手可及。
涵盖领域
本专家意见概述了最新的实验性药物疗法，以预防和恢复感音神经性听力损失。
专家意见
耳蜗的细胞损伤程度和类型、剩余内源性细胞对再生治疗的反应性以及耳蜗液中药物的可用时间将决定听力保护或恢复的成功与否。
Zotero 插件